Business
Monday, April 17, 2017
FDA rejects Eli Lilly's arthritis drug
Shares of Eli Lilly and partner Incyte drop after the U.S. Food and Drug Administration declines to approve a new drug for rheumatoid arthritis. Roselle Chen reports.
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment